Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMVXZJ4)

Drug Name

RetinoStat Drug Info

Synonyms

AngiStat; XiaGen; Cardiovascular disease therapy, Oxford Biomedica; Gene therapy (HRE), Oxford Biomedica; Angiostatin/endostatin gene therapy (LentiVector, AMD), Oxford Biomedica

Indication

Disease Entry	ICD 11	Status	REF
Macular degeneration	9B78.3	Phase 2	[1]

Cross-matching ID

TTD Drug ID: DMVXZJ4

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Investigative Drug(s)

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Endostatin (COL18A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Endo-CD	DM4AI91	Discovery agent	N.A.	Investigative	[2]
------------------------------------------------------------------------------------

Drug(s) Targeting Plasminogen (PLG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ranolazine	DM0C9IL	Acute coronary syndrome	BA41	Approved	[3]
Aminocaproic Acid	DMFGND4	Bleeding disorder	GA20-GA21	Approved	[4]
Streptokinase	DM5JQ0D	Pulmonary embolism	BB00	Approved	[5]
Tranexamic Acid	DMFI8A7	Excessive bleeding	GA30.02	Approved	[6]
Alteplase	DMRJ3YX	Acute myocardial infarction	BA41	Approved	[7]
Tenecteplase	DMJYN25	Acute myocardial infarction	BA41	Approved	[7]
Anistreplase	DM6Q4B0	Acute coronary syndrome	BA41	Approved	[8]
Reteplase	DML0D1P	Heart attack	BA41	Approved	[9]
MELAGATRAN	DM4W8RE	N. A.	N. A.	Phase 3	[10]
Desmoteplase	DMDLU4Z	Ischemic stroke	8B11.5Z	Phase 3	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Endostatin (COL18A1)	TT63DI9	COIA1_HUMAN	Modulator	[1]
Plasminogen (PLG)	TTP86E2	PLMN_HUMAN	Modulator	[1]

------------------------------------------------------------------------------------

References

1	Safety and biodistribution of an equine infectious anemia virus-based gene therapy, RetinoStat( ), for age-related macular degeneration. Hum Gene Ther. 2012 Sep;23(9):980-91.
2	Dual targeting of tumor angiogenesis and chemotherapy by endostatin-cytosine deaminase-uracil phosphoribosyltransferase.Mol Cancer Ther.2011 Aug;10(8):1327-36.
3	Tranexamic acid in trauma: how should we use it. J Trauma Acute Care Surg. 2013 Jun;74(6):1575-86.
4	The blockage of the high-affinity lysine binding sites of plasminogen by EACA significantly inhibits prourokinase-induced plasminogen activation. Biochim Biophys Acta. 2002 Apr 29;1596(2):182-92.
5	Acute anuric renal failure with streptokinase therapy in a patient with acute venous thromboembolic disease and the review of renal side effects of streptokinase. Tuberk Toraks. 2008;56(4):456-61.
6	Evaluation of aprotinin and tranexamic acid in different in vitro and in vivo models of fibrinolysis, coagulation and thrombus formation. J Thromb Haemost. 2007 Oct;5(10):2113-8.
7	Thrombolytic therapies: the current state of affairs. J Endovasc Ther. 2005 Apr;12(2):224-32.
8	Evaluation of thrombolytic agents. Drugs. 1997;54 Suppl 3:11-6; discussion 16-7.
9	Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):212-23.
10	Orally active thrombin inhibitors. Part 1: optimization of the P1-moiety. Bioorg Med Chem Lett. 2006 May 15;16(10):2641-7.
11	Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke. 2003 Feb;34(2):537-43.